A
Anchor Therapeutics
Anchor Therapeutics develops pharmaceutical candidates to address cancer, inflammation, metabolism, heart disease, and pain
About Anchor Therapeutics
Anchor Therapeutics specializes in designing and developing peptide modulators targeting G protein-coupled receptors (GPCRs), which are the largest family of drug targets. The company's proprietary peptides, known as pepducins, modulate GPCR activity through a unique intracellular allosteric mechanism. This innovative approach is well-suited for a wide range of targets, including difficult-to-treat and orphan receptors. Anchor Therapeutics collaborates with pharmaceutical companies to leverage the broad applications of pepducin technology, aiming to create new treatment options for conditions such as regenerative medicine and diabetes. The company operates in the biotechnology sector, serving pharmaceutical firms and research institutions. Its business model revolves around research and development collaborations, licensing agreements, and co-marketing partnerships. Revenue is generated through milestone payments, licensing fees, and royalties from successful drug developments.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2006
- Headquarters
- Cambridge, United States
- Employees
- 3
- Open positions
- None listed
- Dealroom signal
- 54.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
Growth signals
Latest recorded traffic for Anchor Therapeutics is 240 monthly website visits, up 100% over the last three months. Anchor Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Anchor Therapeutics in the Cambridge ecosystem
The Anchor Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
- HVHealthCare Ventures
Novartis Venture Fund
TVM Capital Life Science
Other known investors1 additional known investor
Tufts University
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Anchor Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Anchor Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









